Welcome to our dedicated page for Datatrak Interna news (Ticker: DTRK), a resource for investors and traders seeking the latest updates and insights on Datatrak Interna stock.
Datatrak International, Inc. (OTC:DTRK) is a software-as-a-service provider of enterprise cloud-based technologies and unified eClinical solutions for the life sciences industry. This news page focuses on developments related to Datatrak’s clinical trial software platform, its Datatrak Enterprise Cloud, and its specialized applications such as Datatrak Direct for ePRO, eCOA, and eConsent.
Readers can find coverage of Datatrak’s announcements about its eClinical platform, including updates on decentralized and hybrid clinical trial capabilities, new product launches, and enhancements to modules like EDC, RTSM, eTMF, CTMS, and other integrated functions. News may also highlight contracts and partnerships with contract research organizations (CROs), such as agreements to deploy Datatrak eSource and related data management solutions across multiple studies.
Because Datatrak operates in the life sciences technology space, its news often includes operating results and commentary on trends affecting clinical trials, such as the adoption of remote and virtual trial models. Company releases discuss how Datatrak is reinvesting in its Enterprise Cloud eClinical Platform, adding products like Datatrak Direct and business intelligence capabilities, and expanding sales and marketing efforts around these offerings.
This page brings together Datatrak’s press releases and other public updates so that investors, clinical trial professionals, and other interested readers can review the company’s reported financial results, platform milestones, and product-related announcements in one place. For ongoing insight into Datatrak’s role in clinical trial technology and its OTC-listed stock, visitors can use this news feed as a central reference.
DATATRAK (OTC:DTRK) launched a standalone eConsent solution that deploys in under four weeks, integrates with any EDC, and is available as a lightweight, cost‑effective module or as part of the DATATRAK Powered by Fountayn platform.
The product supports remote and site‑based enrollment, protocol amendments and re‑consent tracking, multi‑device patient access, QR/email invites, and integration with RTSM, CTMS, and eTMF to streamline startup timelines and lower technology costs.
Datatrak (OTC:DTRK) announced that a CRO entered into a $1,800,000 contract for Datatrak eSource on November 11, 2025. The contract covers an end-to-end eClinical suite including EDC, RTSM, eTMF, CTMS, ePRO, eConsent and Global Enterprise Management, delivered through Datatrak's single-login dashboard.
The platform is powered by Fountayn and includes full-service study support from study start-up to closeout with teams in the United States, European Union, and Japan. A demo is available via sales@fountayn.com.
Datatrak International, Inc. (OTC Markets: DTRK) reported its financial results for Q3 and the first nine months of 2021, revealing a decline in revenue to $1.52 million in Q3 2021 from $1.75 million in Q3 2020. The company incurred a net loss of $431,000 compared to a loss of $27,000 in the prior year. Despite these challenges, Datatrak added two new customers in Q3 and extended a contract with a major CRO partner. The backlog decreased to $10.8 million, down from $13.7 million at the end of 2020, indicating potential revenue generation challenges ahead.
Datatrak International (OTC: DTRK) reported its Q2 and H1 2021 operating results, highlighting a 15% increase in revenue-generating contracts and an 11% rise in customers year-over-year. However, Q2 revenue dropped to $1.6M from $1.7M in the previous year, with direct costs increasing to $545K. Despite a gross margin decline from 73% to 66%, Datatrak achieved a net income of $501K, aided by a PPP loan forgiveness. The company's backlog decreased to $12.3M from $13.7M, reflecting concerns about potential revenue generation going forward amidst the ongoing impact of COVID-19.
Datatrak International, Inc. (DTRK) reported its Q1 2021 results, showing a revenue decline to $1,671,000 from $1,951,000 in Q1 2020. Despite this, the company achieved a 14% increase in revenue-generating contracts and an 8% rise in customer numbers. Gross profit margin dropped to 70% from 75%. Datatrak recorded an operational loss of $110,000 compared to a profit of $62,000 in the previous year. Notably, the company's backlog decreased slightly to $13.3 million. The company also secured a $750,000 line of credit with KeyBank.
Datatrak International (OTC: DTRK) has launched Datatrak Direct, an all-in-one app for ePRO, eCOA, and eConsent, now available on iOS and Android. This app aims to enhance data collection for clinical trials by allowing users to enter data anytime, anywhere, and store it securely on the Datatrak Enterprise Cloud. Key features include drag-and-drop trial design tools and automation of workflows to reduce human errors. The launch responds to a growing demand for decentralized trials, improving patient engagement and data accuracy.